The pharma ADMET testing market is estimated at $7.43bn in 2016 and is expected to grow at a CAGR of 12.32% in the first half of the forecast period. The market is expected to grow at a CAGR of 10.50% in the second half of the forecast period. In 2016, the largest sector of the market was in vitro testing, which accounted for 44.3% of the ADMET testing market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 149-page report you will receive 100 charts– all unavailable elsewhere.
The 149-page report provides clear detailed insight into the pharma ADMET testing market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Pharma ADMET Testing market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the main submarkets: – In Vivo ADMET Testing – In Vitro ADMET Testing – In Silico ADMET Testing
• This report provides individual revenue forecasts to 2027 for these regional and national markets: – The US – Japan – Germany – France – Italy – Spain – The UK – China – Brazil – Russia – India – South Korea – Rest of the World
• Our study includes SWOT and STEP analysis of this industry and market.
• Our study discusses the selected leading companies that are the major players in the ADMET Testing industry: – Agilent Technologies – BIOVIA – Cyprotex – Bio-Rad Laboratories – Quintiles – CMIC – Charles River Laboratories – WuXi PharmaTech – Promega Corporation – Sigma-Aldrich (part of Merck KGaA)
A company profile gives you the following information where available: • Recent historical revenues • Discussion of a company’s activities, technologies and outlook • Brief assessment of the company’s ADMET strategy
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma ADMET Testing market. You find data, trends and predictions.
Buy our report today Pharma ADMET Testing Market 2017-2027: In Vitro, In Vivo, In Silico, Leading Developed Markets, Leading Emerging Markets, Leading Companies.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the World Market for ADMET Testing 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analysis 1.5 Who Is This Study For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain
2. An Introduction to ADMET Testing 2.1 What Is ADMET Testing? 2.1.1 Absorption 2.1.2 Distribution 2.1.3 Metabolism 2.1.3.1 MIST Guidelines 2.1.4 Excretion 2.1.5 Toxicology 2.2 The Role of ADMET Testing in Biosimilarity 2.3 Trial Design and Execution 2.3.1 Phases of Drug Development 2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties 2.3.1.2 Phase I Trials: First-In-Human Studies 2.3.1.3 Phase II Trials: Proof-Of-Concept 2.3.1.4 Phase III Trials: Preparing for Approval Applications 2.3.1.5 Post-Marketing Studies 2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET 2.3.3 Benefits of Outsourcing
3. ADMET Testing: World Market 2015-2027 3.1 Pharma R&D Expenditures by Phase, 2014 3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014 3.1.2 Big Pharma Companies Are the Leading Clients for CROs 3.2 The ADMET Testing Market 2015-2027 3.2.1 What Will Drive Growth in ADMET Testing 2015-2027? 3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2027
4. ADMET Testing: Revenue by Segment 2015-2027 4.1 Which Market Sector Will Account for the Most Revenue from 2015-2027? 4.2 Rising Demand for Predictive ADMET Testing Throughout the Decade 4.3 In Vitro ADMET Testing Market 4.3.1 In Vitro ADMET Testing: Drivers and Restraints 4.4 In Vivo ADMET Testing Market 4.4.1 In Vivo ADMET Testing: Drivers and Restraints 4.5 In Silico ADMET Testing 4.5.1 In Silico ADMET Testing: Drivers and Restraints
5. ADMET Testing: Leading Developed Markets 2015-2027 5.1 Leading National Markets for ADMET Testing 2016 5.2 ADMET Testing: Leading National Market Forecasts 2015-2027 5.3 North America as a Destination for Drug Development 5.3.1 The US: The Largest National Market for ADMET Testing 2015-2027 5.3.1.1 Government Programs to Improve ADMET in the US 5.3.2 The US: ADMET Testing Revenue Forecast 2015-2027 5.4 The Outlook for ADMET Testing in the EU5 2015-2027 5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation 5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2027 5.4.3 Germany: Market Forecast 2015-2027 5.4.4 The UK 5.4.4.1 Overcoming Challenges in UK Clinical Trials 5.4.4.2 UK ADMET Testing Market Forecast 2015-2027 5.4.5 France: Market Forecast 2015-2027 5.4.6 Italy: Market Forecast 2015-2027 5.4.7 Spain: Market Forecast 2015-2027 5.5 Japan Is Being Challenged by Neighbouring Emerging Markets 5.5.1 Growth for ADMET Testing in Japan 2015-2027
6. ADMET: Leading Emerging Markets 2015-2027 6.1 Leading Emerging Markets for ADMET Testing 2016 6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets 6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets 6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2027 6.3 ADMET in Asia Pacific: An Emerging Market Perspective 6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025 6.3.1.1 CRO Investments and Partnerships in China 6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2027 6.3.2 India as a Hub for Clinical Trials 6.3.2.1 Indian ADMET Testing Market Forecast 2015-2027 6.3.3 South Korea 6.3.3.1 Promoting Local Drug Development in South Korea 6.3.3.2 Growth in the South Korean ADMET Market 2015-2027 6.4 Russia 6.4.1 Changing Drug Development Demands 2010-2015 6.4.2 Russian ADMET Market Forecast 2015-2027 6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2027 6.5.1 Brazilian ADMET Testing Market Forecast 2015-2027
7. Leading Companies in the ADMET Testing Industry 7.1 Agilent Technologies, Inc. 7.1.1 Agilent Technologies, Inc.: Historical Revenues 2014-2016 7.1.2 Agilent Technologies, Inc. Acquires Cartagenia 7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA 7.2.1 Accelrys: Historical Revenues 2011-2013 7.3 Cyprotex 7.3.1 Evotec AG acquires Cyprotex 7.3.2 Cyprotex Acquires CeeTox 7.3.3 Cyprotex Historical Revenues, 2010-2014 7.4 Bio-Rad Laboratories, Inc. 7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2014-2016 7.5 Quintiles 7.5.1 Merger with IMS Health 7.5.2 Expanding in Developed and Emerging Markets 7.6 Increasing Asian Regional Reach 7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist 7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services 7.8 WuXi PharmaTech 7.8.1 Merger with New WuXi Life Science Limited and WuXi Merger Limited 7.8.2 WuXi Acquires XenoBiotic Laboratories 7.8.3 WuXi Enters the Clinical Trial Services Market 7.9 Promega Corporation 7.10 Merck KGaA’s Acquisition of Sigma Aldrich
8. ADMET Testing Market: Industry Trends 2015-2027 8.1 Strengths and Weaknesses of the ADMET Testing Market 8.2 Opportunities and Threats in the ADMET Testing Market 8.3 ADMET Testing Market: STEP Analysis 2015-2027 8.3.1 Social Factors Affecting ADMET 2015-2027 8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing 8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models 8.5 Economic Considerations for ADMET Testing 2015-2027 8.5.1 Demand for Predictive ADMET Testing 8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2027 8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development 8.6.2 Strategic Partnering for Long Term Revenue Growth 8.6.2.1 Sharing Risk Between Pharma and CROs 8.6.3 A Note on CRO Selection 8.6.3.1 Small Pharmaceutical Companies and CROs 8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players
9. Conclusions from Our Study 9.1 The World ADMET Testing Market in 2016 9.1.1 A Market Dominated by the Developed Countries 9.2 Strong Growth for the Overall Market 2015-2027 9.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years? 9.3.1 How Can CROs Specialise to Remain Competitive?
Appendices Visiongain’s Bespoke Research Service Some Associated Reports Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 1.1 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015 and 2016 Table 2.1 Pharmacokinetics: Description of ADME Table 2.2 Drug Delivery Routes Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015 Table 2.4 Founding Members of the ICH Table 3.1 Breakdown of R&D Expenditures by Phase, 2014 Table 3.2 CRO Services Revenue by Customer Type, 2014 Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2017, 2020, and 2027 Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2016 Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.3 ADMET Testing: Market Shares by Country, 2016, 2020 and 2027 Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.5 EU5 ADMET Testing Market by Country, 2016 Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 6.1 Leading Emerging Markets for ADMET Testing, 2016 Table 6.2 Population Statistics in BRIC Nations, 2016 Table 6.3 English Proficiency in Emerging Markets, 2014 Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027 Table 7.1 Selected Companies in the ADMET Testing Industry, 2016 Table 7.2 Selected Agilent Technologies MS Products, 2016 Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2014-2016 Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2015 and 2016 Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013 Table 7.6 Cyprotex ADME & PK Services, 2016 Table 7.7 Cyprotex In Vitro Toxicology Services, 2016 Table 7.8 Cyprotex In Silico Services, 2016 Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014 Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2014-2016 Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2014-2016 Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2014-2016 Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2015 and 2016 Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014 Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2016 Table 8.2 ADMET Testing Market: Opportunities and Threats, 2016 Table 8.3 ADMET Testing Market: STEP Analysis, 2016 Table 9.1 ADMET Testing Market by Sector: Revenue ($bn) and CAGR (%), 2016, 2020 & 2027
List of Figures Figure 2.1 Drug Design Process Figure 2.2 ADMET Parameters Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014 Figure 3.2 CRO Services Revenue by Customer Type, 2014 Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2027 Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2017, 2020 and 2027 Figure 4.2 ADMET Testing Submarket Shares (%), 2017 Figure 4.3 ADMET Testing Submarket Shares (%), 2020 Figure 4.4 ADMET Testing Submarket Shares (%), 2027 Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2027 Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2027 Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2027 Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2027 Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2027 Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2027 Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2027 Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2016 Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2020 Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2027 Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2016 Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2016 Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014 Figure 6.3 Relative Competence in English in Emerging Markets, 2014 Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2027 Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2027 Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2014-2016 Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2016 Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013 Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014 Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2014-2016 Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2014-2016 Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR(%), 2014-2016 Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2015 and 2016 Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014 Figure 9.1 ADMET Testing Market Revenue ($bn) by Sector, 2016, 2020 & 2027
AbD Serotec (now part of Bio-Rad Laboratories) ACEA Biosciences Aegis Analytical Corp Agilent Technologies Albany Molecular Research Apredica, LLC AstraZeneca Bayer BD Biosciences Beckman Coulter Bio-Rad Laboratories BIOVIA Boehringer Ingelheim Caliper Life Sciences Cambridge Cell Networks Catalent Pharma Solutions Catalina Health (now part of InVentiv Health) Celerion Cellartis Cellectis AB Cellumen Celsis International Charles River Laboratories ChemSW Clinipace Worldwide ClinStar (now part of PRA Health Sciences) CMIC Holdings Cromos Pharma CROMSOURCE Cyprotex EF Education First Entelos Holdings EPS Holdings, Inc., formerly EPS Corporation Frontage Laboratories GCP ClinPlus I3 Research (now part of InVentiv Health) ICON plc INC Research InVentiv Health Harlan Laboratories (now part of Huntingdon Life Sciences) Hisun Pharmaceuticals Hospital Italiano of Buenos Aires Huntingdon Life Sciences JCL Bioassay Corporation (now part of CMIC) Kendle (now part of INC Research) Kforce Clinical Research (now part of InVentiv Health) Life Technologies Corporation LSK Malaysian Biotechnology Corporation Merck & Co. Merck KGaA Mitsubishi Gas Chemical Company, Inc. MultiCASE New York Stock Exchange Noray Bioinformatics Novartis Novotech Oncobiologics Optivia Biotechnology Organovo Holdings, Inc. Parexel PerkinElmer Pharmaron PharmaNet Development Group (now part of InVentiv Health) PRA Health Sciences Prodia Clinical Laboratory Promega Corporation Proteomics ProTrials Research Quintiles ReSearch Pharmaceutical Services (now part of PRA Health Sciences) Rosa & Co Samsung Sekisui Medical Co. ShangPharma Sigma-Aldrich Simulations Plus Sugi Medical Co. (now part of CMIC) Taconic Biosciences Takara Bio Europe AB Takara Bio Inc Tecan Group Thermo Fisher Scientific Tigermed Consulting VelQuest Vialis West Coast Clinical Trials WuXi PharmaTech Xceleron XenoBiotic Laboratories XenoTech (now part of Sekisui) Yungjin Pharmaceutical Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd
Organizations Mentioned in the Report Agenzia Italiana del Farmaco Agência Nacional de Vigilância Sanitária (ANVISA) Associação Brasileira de CROs Association of Clinical Trial Organisations (ACTO) [Russia] Chinese Ministry of Commerce Council for Economic Defense [Brazil] Department of Health and Human Services [US] Environmental Protection Agency [US] European Commission European Medicines Agency (EMA) Fish and Wildlife Service [US] Food and Drug Administration (FDA) [US] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Helmholtz Association Helmholtz Zentrum München (German Research Center for Environmental Health) Korea Drug Development Fund Korea Food and Drug Administration (KFDA) Korea National Enterprise for Clinical Trials L'Agence Nationale de Sécurité du Médicament (l’ANSM) Les Entreprises du Medicament (LEEM) Medicines and Healthcare Products Regulatory Agency (MHRA) [UK] Nagoya University National Association for Biomedical Research [US] National Cancer Institute (NCI) [US] National Center for Advancing Translational Sciences [US] National Centre for Computational Toxicology [US} National Enterprise for Clinical Trials [South Korea] National Human Genome Research Institute [US] National Institute of Environmental Health Sciences [US] National Institutes of Health (NIH) [US] National Toxicology Program [US] New England Antivivisection Society Russian Ministry of Public Health Seoul National University Hospital Clinical Trials Center Shanghai Clinical Research Center Vietnam Ministry of Health Administration of Science, Technology and Training (ASST) World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Pharma ADMET Testing Market 2017-2027
Download sample pages
Complete the form below to download your free sample pages for Pharma ADMET Testing Market 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
